Talk:COVID-19 drug development

This is the talk page for discussing improvements to the COVID-19 drug development article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Archives: 1: 14 days

COVID-19 High‑importance

	COVID-19 portal This article is within the scope of WikiProject COVID-19, a project to coordinate efforts to improve all COVID-19-related articles. If you would like to help, you are invited to join and to participate in project discussions.COVID-19Wikipedia:WikiProject COVID-19Template:WikiProject COVID-19COVID-19 articles
High	This article has been rated as High-importance on the project's importance scale.
	An editor has requested that an image or photograph be added to this article.

Medicine: Pulmonology Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	This article is supported by the Pulmonology task force (assessed as Mid-importance).
	An editor has requested that an image or photograph be added to this article.

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Viruses Mid‑importance

	Viruses portal This article is within the scope of WikiProject Viruses, a collaborative effort to improve the coverage of viruses on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.VirusesWikipedia:WikiProject VirusesTemplate:WikiProject Virusesvirus articles
Mid	This article has been rated as Mid-importance on the project's importance scale.
	An editor has requested that an image or photograph be added to this article.

project's importance scale

.

International relations Mid‑importance

	This article is within the scope of WikiProject International relations, a collaborative effort to improve the coverage of International relations on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.International relationsWikipedia:WikiProject International relationsTemplate:WikiProject International relationsInternational relations articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

WikiProject COVID-19 consensus

WikiProject COVID-19 aims to add to and build

consensus for pages relating to COVID-19. They have so far discussed items listed below. Please discuss proposed improvements to them at the project talk page

.

General

Superseded by TfD October 2020 and later practice - consult regular {{Current}} guidance.

Refrain from using April 2020
)

For infoboxes on the main articles of countries, use Wuhan, Hubei, China for the origin parameter. (March 2020)

"Social distancing" is generally preferred over "physical distancing". (April 2020, May 2020)

Page title

COVID-19 (full caps) is preferable in the body of all articles, and in the title of all articles/category pages/etc.(RM April 2020, including the main article itself, RM March 2021).

SARS-CoV-2 (exact capitalisation and punctuation) is the common name of the virus and should be used for the main article's title, as well as in the body of all articles, and in the title of all other articles/category pages/etc. (June 2022, overturning April 2020)

Map

There is no consensus about which color schemes to use, but they should be consistent within articles as much as possible. There is agreement that there should be six levels of shading, plus gray for areas with no instances or no data. (May 2020)

There is no consensus about whether the legend, the date, and other elements should appear in the map image itself. (May 2020)

For map legends, ranges should use fixed round numbers (as opposed to updating dynamically). There is no consensus on what base population to use for per capita maps. (May 2020)

To ensure you are viewing the current list, you may wish to purge this page.

Daily pageviews of this article

A graph should have been displayed here but graphs are temporarily disabled. Until they are enabled again, visit the interactive graph at pageviews.wmcloud.org

The contentious topics procedure applies to this page. This page is related to COVID-19, broadly construed, which has been designated as a contentious topic.

Editors who repeatedly or seriously fail to adhere to the purpose of Wikipedia, any expected standards of behaviour, or any normal editorial process may be blocked or restricted by an administrator. Editors are advised to familiarise themselves with the contentious topics procedures before editing this page.

Include interferon lambda in the list of drugs being tested for COVID.

Multiple clinical trials are investigating the use of Interferon Lambda to treat COVID.^[1]^[2]^[3]

References

Add sabizabulin

Sabizabulin "halved the death rate among critically ill Covid patients who were receiving supplemental oxygen and were at high risk for serious lung disease and death"

New Drug Slashed Deaths Among Patients With Severe Covid, Maker Claims https://www.nytimes.com/2022/04/11/health/covid-sabizabulin-veru.html

National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 53379371, Sabizabulin. Retrieved April 12, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Sabizabulin

Sabizabulin (VERU-111) for COVID-19 https://verupharma.com/pipeline/sabizabulin-for-covid-19/

Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy https://www.globenewswire.com/news-release/2022/04/11/2419839/11676/en/Veru-s-Novel-COVID-19-Drug-Candidate-Reduces-Deaths-by-55-in-Hospitalized-Patients-in-Interim-Analysis-of-Phase-3-Study-Independent-Data-Monitoring-Committee-Halts-Study-Early-for-.html

2600:1000:B00F:64AC:D8E9:99AA:2866:936 (talk) 13:50, 12 April 2022 (UTC)[reply]

Thanks for posting this. We would not use the press releases as

reliable sources for this information, so need to wait for peer reviewed articles or independent newspaper reports before including the supposed efficacy. In addition, this might be more suitable for this article - COVID-19 drug repurposing research

- as the drug was in development already for cancer. Either way, I expect there will be more information published soon and if the press report is borne out then it should be included.

Currently, one review lists the trial in a table , and it has a listing on ClinicalTrials.gov. |→ Spaully ^~talk~ 14:14, 12 April 2022 (UTC)[reply]

Semi-protected edit request on 28 July 2023

This edit request has been answered. Set the |answered= or |ans= parameter to no to reactivate your request.

‹ The template Edit semi-protected is being considered for merging. ›

Specia = Special 2603:8000:D300:D0F:2098:B4E2:5069:2E94 (talk) 04:55, 28 July 2023 (UTC)[reply]

Not done: That appears to be a person's last name, located in a reference to this article which lists Megan Specia as an author. Tollens (talk) 05:13, 28 July 2023 (UTC)[reply]

[1] ttps://clinicaltrials.gov/ct2/show/NCT04354259

[2] ttps://clinicaltrials.gov/ct2/show/NCT04354259

[3] ttps://clinicaltrials.gov/ct2/show/NCT04331899

[1]

[2]

[3]